trending Market Intelligence /marketintelligence/en/news-insights/trending/ZZZaYj15_-6GLTJCB6A_mw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Former Regulus Therapeutics exec joins AmpliPhi Biosciences as CEO

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Former Regulus Therapeutics exec joins AmpliPhi Biosciences as CEO

AmpliPhi Biosciences Corp. appointed Paul Grint to the position of CEO, effective May 31.

Grint previously worked as president and CEO of biopharmaceutical company Regulus Therapeutics Inc.

M. Scott Salka has resigned as CEO and director of AmpliPhi and will serve as a consultant to the company during a transition period.